Advertisement

Anakinra for macrophage activation syndrome

Published:January 05, 2023DOI:https://doi.org/10.1016/j.ejim.2023.01.002
      Macrophage activation syndrome (MAS) is a serious, life-threatening, complication, characterized by generalized, multisystem, inflammatory response, which can affect almost every organ system, resulting in multiple organ dysfunction [
      • Ravelli A.
      • Davì S.
      • Minoia F.
      • Martini A.
      • Cron R.Q.
      Macrophage activation syndrome.
      ]. Rheumatic diseases, infections, hematologic malignancies, and certain drug classes have been identified as potential triggers of MAS [
      • Ravelli A.
      • Davì S.
      • Minoia F.
      • Martini A.
      • Cron R.Q.
      Macrophage activation syndrome.
      ,
      • Karakike E.
      • Giamarellos-Bourboulis E.J.
      Macrophage Activation-like syndrome: a distinct entity leading to early death in sepsis.
      ]. Interleukin (IL)−1β over-secretion provokes to cytokine storm, involving IL-6, IL-18 and interferon-γ, which contribute to multiple organ dysfunction [
      • Karakike E.
      • Giamarellos-Bourboulis E.J.
      Macrophage Activation-like syndrome: a distinct entity leading to early death in sepsis.
      ]. Therefore, despite the fact that corticosteroids and cyclosporine remain the cornerstone for the treatment of MAS, anti-cytokine biologic therapies have also emerged as potential treatment options for this entity [
      • Tang S.
      • Li S.
      • Zheng S.
      • et al.
      Understanding of cytokines and targeted therapy in macrophage activation syndrome.
      ].
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ravelli A.
        • Davì S.
        • Minoia F.
        • Martini A.
        • Cron R.Q.
        Macrophage activation syndrome.
        Hematol Oncol Clin N Am. 2015; 29: 927-941https://doi.org/10.1016/j.hoc.2015.06.010
        • Karakike E.
        • Giamarellos-Bourboulis E.J.
        Macrophage Activation-like syndrome: a distinct entity leading to early death in sepsis.
        Front Immunol. 2019; 10 (Published 2019 Jan 31): 55https://doi.org/10.3389/fimmu.2019.00055
        • Tang S.
        • Li S.
        • Zheng S.
        • et al.
        Understanding of cytokines and targeted therapy in macrophage activation syndrome.
        Semin Arthritis Rheum. 2021; 51: 198-210https://doi.org/10.1016/j.semarthrit.2020.12.007
        • Sönmez H.E.
        • Demir S.
        • Bilginer Y.
        • Özen S.
        Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature.
        Clin Rheumatol. 2018; 37: 3329-3335https://doi.org/10.1007/s10067-018-4095-1
        • Cavalli G.
        • Farina N.
        • Campochiaro C.
        • Baldissera E.
        • Dagna L.
        Current treatment options and safety considerations when treating adult-onset Still's disease.
        Expert Opin Drug Saf. 2020; 19: 1549-1558https://doi.org/10.1080/14740338.2020.1839411
        • Campochiaro C.
        • Farina N.
        • Tomelleri A.
        • et al.
        Drug retention rates of biological agents in adult onset Still's disease.
        Semin Arthritis Rheum. 2021; 51: 1-6https://doi.org/10.1016/j.semarthrit.2020.09.014
        • Leventogiannis K.
        • Kyriazopoulou E.
        • Antonakos N.
        • et al.
        Toward personalized immunotherapy in sepsis: the PROVIDE randomized clinical trial.
        Cell Rep Med. 2022; 3100817https://doi.org/10.1016/j.xcrm.2022.100817
        • Shakoory B.
        • Carcillo J.A.
        • Chatham W.W.
        • et al.
        Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial.
        Crit Care Med. 2016; 44: 275-281https://doi.org/10.1097/CCM.0000000000001402
        • Karakike E.
        • Dalekos G.N.
        • Koutsodimitropoulos I.
        • et al.
        ESCAPE: an open-label trial of personalized immunotherapy in critically lll COVID-19 patients.
        J Innate Immun. 2022; 14: 218-228https://doi.org/10.1159/000519090
        • Campochiaro C.
        • Farina N.
        • Tomelleri A.
        • De Luca G.
        • Cavalli G.
        • Dagna L.
        Patients' experience and tolerability with canakinumab and anakinra for the treatment of adult-onset Still's disease.
        Clin Exp Rheumatol. 2022; 40: 1598-1599https://doi.org/10.55563/clinexprheumatol/iqdzl9